Final FDA Waiver Guidance For Point-Of-Care Diagnostics Unduly Burdensome, Industry Org. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-awaited FDA guidance for point-of-care diagnostics to be used in less-sophisticated settings offers leeway in clinical trial design but not enough for industry.
You may also be interested in...
The New Diagnostics Companies
A small number of start-ups are developing novel specilalty-focused diagnostics that capture drug-like revenues and margins without taking drug-like development and regulatory risks. Questions about the business model abound, since most companies need multiple tests to reach profitability and a changing regulatory climate may force these companies to seek FDA approval for their tests, dramatically increasing development risk and cost.
Industry Involvement In Guidance Development Encouraged By FDA Working Group
In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.
Industry Involvement In Guidance Development Encouraged By FDA Working Group
In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.